Colgate-Palmolive Croissance future
Future contrôle des critères 2/6
Colgate-Palmolive devrait augmenter ses bénéfices et son chiffre d'affaires de 12.1% et de 3.2% par an respectivement. Le BPA devrait croître de de 13.2% par an. Le rendement des capitaux propres devrait être 255.3% dans 3 ans.
Informations clés
12.1%
Taux de croissance des bénéfices
13.16%
Taux de croissance du BPA
| Household Products croissance des bénéfices | 4.6% |
| Taux de croissance des recettes | 3.2% |
| Rendement futur des capitaux propres | 255.29% |
| Couverture par les analystes | Good |
| Dernière mise à jour | 12 May 2026 |
Mises à jour récentes de la croissance future
Recent updates
Seeking Alpha • May 10
Colgate-Palmolive: Too Expensive For A Defensive Firm
Summary Colgate-Palmolive delivered 8% sales growth in Q1 2026, but EPS declined 6%, warranting a conservative hold rating. I see organic growth of just 2.9%, with North America sales falling due to increased toothpaste competition and margin compression. FX tailwinds drove significant growth in Latin America, EMEA, and APAC, raising concerns about sustainability if currency trends reverse. Persistent low U.S. consumer confidence and elevated input costs, including a $300M Middle East impact, create near-term headwinds for CL. Read the full article on Seeking Alpha
Mise à jour du récit • Apr 09
CL: 2030 Plan Execution And Margins Will Shape 2026 Setup
Analysts have trimmed the Colgate-Palmolive fair value estimate by about $0.58 to $96.68, reflecting slightly softer revenue growth assumptions, a modestly lower future P/E, and mixed recent research that includes both reduced price targets and an upgrade tied to confidence in the 2030 plan and ongoing margin resilience. Analyst Commentary Recent Street research on Colgate-Palmolive shows a mix of optimism around the long-term plan and caution around nearer term cost and valuation risks.Mise à jour du récit • Mar 25
CL: 2030 Plan And Emerging Markets Execution Will Shape 2026 Setup
Colgate-Palmolive's fair value estimate edges up to $97.26 from $97.21 as analysts lift price targets toward the $100 to $105 range, citing stronger confidence in the 2030 plan, product innovation, and emerging markets execution. Analyst Commentary Recent Street research on Colgate-Palmolive clusters around higher price targets and upgraded ratings, with the fair value conversation increasingly framed around the 2030 plan, execution in emerging markets, and portfolio moves such as the exit from private label pet food.Mise à jour du récit • Mar 10
CL: 2030 Plan And Emerging Markets Support Measured 2026 Execution Setup
Analysts have nudged their price expectations for Colgate-Palmolive higher, with the updated fair value estimate moving from about $96.68 to roughly $97.21. They cite growing confidence in the company’s 2030 plan, product innovation efforts and emerging markets exposure, as reflected in a series of recent price target increases across major firms.Mise à jour du récit • Feb 24
CL: 2030 Plan And Emerging Markets Will Drive Balanced 2026 Setup
Analysts have raised their implied price target for Colgate-Palmolive by about $8 to reflect higher conviction in the company’s 2030 plan, product innovation pipeline and emerging market exposure, as well as refreshed views on sector valuations. Analyst Commentary Recent research has centered on how Colgate-Palmolive’s 2030 plan, product pipeline and emerging market footprint feed into both growth potential and current valuation.Article d’analyse • Feb 06
There May Be Some Bright Spots In Colgate-Palmolive's (NYSE:CL) Earnings
Colgate-Palmolive Company's ( NYSE:CL ) recent soft profit numbers didn't appear to worry shareholders, as the stock...Mise à jour du récit • Jan 28
CL: Emerging Markets And 2026 Setup Will Shape Balanced Risk Reward
Analysts have nudged their price targets for Colgate-Palmolive higher, reflected in a modest fair value move from about $87.47 to $88.89. They are factoring in slightly stronger revenue growth assumptions, a marginally higher future P/E and recent rating and target changes across firms such as Barclays, JPMorgan, UBS, Wells Fargo, Piper Sandler and TD Cowen.Mise à jour du récit • Jan 10
CL: Emerging Markets And 2026 Setup Support Balanced Outlook After Recent Softness
Our updated analyst price target for Colgate-Palmolive edges up to about US$87.47 from roughly US$87.21, as analysts balance slightly softer modeled revenue growth with modestly higher profit margin and future P/E assumptions. This view is supported by recent research that pairs cautious consumer staples outlooks with a more positive stance on the company’s emerging markets exposure and potential 2026 acceleration.Mise à jour du récit • Dec 15
CL: Emerging Market Strength Will Support Gradual Recovery As Q3 Softness Fades
Analysts have trimmed their price target on Colgate-Palmolive to $87 from the low-to-mid $90s, reflecting near term softness in Q3 results and muted personal care growth, even as they expect organic sales momentum to gradually improve. Analyst Commentary Analysts remain divided on Colgate-Palmolive, with recent target cuts reflecting near term execution risk, while longer term growth and margin recovery expectations stay largely intact.Mise à jour du récit • Nov 30
CL: Gradual Recovery Expected As Temporary Headwinds Ease In Personal Care Markets
Narrative Update on Colgate-Palmolive Colgate-Palmolive's analyst price target has been modestly reduced by $0.05 to $87.21. Analysts cite near-term growth challenges and muted sector outlooks following a soft Q3, but expect gradual improvement as temporary pressures ease.Mise à jour du récit • Nov 16
CL: Organic Sales Momentum Will Rebound As Near-Term Headwinds Ease
Colgate-Palmolive's analyst consensus price target was revised downward from approximately $88.84 to $87.26. Analysts cite a soft third quarter, moderated growth expectations, and ongoing category headwinds as key factors behind the adjustment.Mise à jour du récit • Nov 02
CL: Future Cost Optimization Will Drive Competitive Advantage Amid Category Headwinds
Colgate-Palmolive’s fair value estimate has been reduced from $90.74 to $88.84 per share. Analysts cite persistent category headwinds and a moderated sales outlook as factors behind lower price targets across the sector.Mise à jour du récit • Oct 18
Emerging Markets And Digital Transformation Will Unlock Global Value
Colgate-Palmolive's analyst fair value price target has decreased from $93.11 to $90.74. Analysts cite lowered sales guidance, persistent category headwinds, and muted growth outlooks as key factors behind their revised estimates.Mise à jour du récit • Oct 03
Emerging Markets And Digital Transformation Will Unlock Global Value
Colgate-Palmolive's analyst price target has been revised downward by approximately $2 to $93. Analysts cite ongoing category headwinds and decelerating growth in the personal care sector as reasons for this adjustment.Article d’analyse • Sep 30
There's Reason For Concern Over Colgate-Palmolive Company's (NYSE:CL) Price
Colgate-Palmolive Company's ( NYSE:CL ) price-to-earnings (or "P/E") ratio of 22.3x might make it look like a sell...Article d’analyse • Aug 04
Colgate-Palmolive Company (NYSE:CL) Second-Quarter Results Just Came Out: Here's What Analysts Are Forecasting For This Year
Shareholders might have noticed that Colgate-Palmolive Company ( NYSE:CL ) filed its quarterly result this time last...Article d’analyse • Jun 27
Colgate-Palmolive (NYSE:CL) Has A Pretty Healthy Balance Sheet
Warren Buffett famously said, 'Volatility is far from synonymous with risk.' When we think about how risky a company...Article d’analyse • Jun 12
Do Colgate-Palmolive's (NYSE:CL) Earnings Warrant Your Attention?
For beginners, it can seem like a good idea (and an exciting prospect) to buy a company that tells a good story to...Seeking Alpha • Apr 22
A Historic Brand, A Fresh Approach: Inside Colgate-Palmolive's Machine
Summary Colgate-Palmolive achieved over $20 billion in revenue in 2024, driven by strong brand identity, operational discipline, and a diversified product portfolio across Oral Care, Personal Care, Home Care, and Pet Nutrition. The company maintained profitability despite inflation, with a 14.4% margin, and continued to invest in marketing and R&D, enhancing brand differentiation and price stability. Financially robust, Colgate-Palmolive showed significant revenue and margin growth, generating record free cash flow, and is well-positioned for 2025 with a "Buy" rating and a target share price of $100.08. Key risks include currency fluctuations, raw material costs, and competition, but strong daily demand for products and innovation in high-growth segments like Pet Nutrition support long-term growth. Read the full article on Seeking AlphaSeeking Alpha • Mar 20
Colgate-Palmolive: A Defensive Stock With Growth Potential
Summary Colgate-Palmolive is one of the leaders in the global toothpaste market. On January 31, Colgate-Palmolive released financial results that left me with mixed reactions. Demand for its products in Latin America is growing rapidly, but the strengthening of the US dollar has not allowed Colgate-Palmolive to fully reflect this in its EPS. In this article, you, Seeking Alpha readers, will learn why, according to my "ALLKA 4D Rating" model, Colgate-Palmolive is a stock with an attractive risk/reward ratio. Read the full article on Seeking AlphaSeeking Alpha • Mar 14
Is Colgate-Palmolive Quietly Building The Next Pet Food Empire?
Summary Colgate-Palmolive's premiumization strategy and pet nutrition expansion offer significant growth potential, with a price target of $115 per share, suggesting a 26% upside. Despite high valuation metrics, CL's superior profitability, high margins, and exceptional cash flow justify its premium valuation and long-term investment appeal. The company's strong pricing power, particularly in premium oral care and pet food, positions it well against inflation and competitive pressures. Risks include potential valuation compression and competition in pet nutrition, but CL's consistent cash flow and brand strength mitigate these concerns. Read the full article on Seeking AlphaSeeking Alpha • Feb 25
Colgate-Palmolive: Don't Get Your Hopes Up (Yet)
Summary After a strong first half of 2024, Colgate-Palmolive's stock continues to be an underperformer in the consumer staples sector. The stock is trading at a discount to the level implied by current margins, but there is a good reason for that. Margins are likely to come under pressure in 2025 and from a dividend point of view, CL also appears unattractive at the moment. Read the full article on Seeking AlphaSeeking Alpha • Jan 31
Colgate-Palmolive Stock: Post-Earnings Drop Isn't A Buy-The-Dip Moment
Summary Toothpaste and manual toothbrushes market leader Colgate-Palmolive Company released its fourth quarter and full-year 2024 results today. Judging by the share price reaction, and considering CL stock is down more than 20% from its all-time high, this clearly looks like a “buy the dip” moment. However, I'll explain why I don't think it's a good idea to buy CL shares, either for dividend or total return investors, and despite the company's undoubtedly solid 2024 performance. Read the full article on Seeking AlphaSeeking Alpha • Dec 17
Colgate-Palmolive: Digital Advertising Is The Base From Which To Start Again
Summary Colgate-Palmolive's (CL) revenue growth has been minimal over the past decade, with a CAGR of only 1.53%, not even keeping pace with inflation. Despite a 61-year streak of increasing dividends, CL's EPS growth has been stagnant, leading to a higher payout ratio. Increased advertising expenditures, particularly in digital, have shown higher ROI than traditional channels. CL's future growth may hinge on digital advertising and expanding into Personal and Home Care markets, but the current valuation is too high for a buy rating. Read the full article on Seeking AlphaSeeking Alpha • Dec 11
Colgate-Palmolive: Approaching Buy Territory With Some Important Catalysts
Summary As expected, Colgate-Palmolive's stock has retreated from its recent highs over the past few months. Upside potential for 2025 remains limited as gross margin tailwinds are fading. Nonetheless, there are some key areas that investors should keep a close eye on over the course of next year. Read the full article on Seeking AlphaSeeking Alpha • Oct 25
Colgate-Palmolive Q3: Great Company, But Not Enough To Warrant A Position Now
Summary Colgate-Palmolive Company's Q3 earnings showed mixed results, with revenue and EPS beating estimates but North America and Latin America sales declining, leading to a 3% stock drop. The company's improved gross margins and increased advertising spend are positive signs, but the market remains concerned about regional sales declines. The Pet Nutrition segment shows strong growth potential, driven by the pet humanization trend, and could be a key revenue catalyst. Given macroeconomic uncertainties and regional performance, I rate Colgate-Palmolive stock as a hold, awaiting further developments in NA, LatAm, and Pet Nutrition segments. Read the full article on Seeking AlphaSeeking Alpha • Oct 17
Colgate-Palmolive: Very Close To A Buy Following Recent Pullback
Summary Colgate-Palmolive is a high-quality business with consistent revenue growth, stable gross profit margins, and a strong return on invested capital, making it a solid dividend stock. The company has an impressive 61-year streak of consecutive dividend growth, maintaining a healthy payout ratio of around 60%, ensuring future dividend increases. The recent pace of dividend growth is below par but in line with inflation and top-line business growth. The recent pullback has brought the share price down very close to fair value. With earnings around the corner now may be a good time to consider jumping aboard. Colgate has beaten earnings estimates during the last 5 consecutive quarters, and recent analyst revisions indicate FQ3 may follow suit. Read the full article on Seeking AlphaSeeking Alpha • Sep 30
Colgate-Palmolive: Share Price Returns Should Moderate (Rating Downgrade)
Summary Since I turned bullish on the stock, Colgate-Palmolive delivered a 36% total return in less than 10 months. For a consumer staples company the size of CL, returns will most likely moderate from here for two main reasons. As the impact of pricing initiatives fades away, investors should keep a close eye on volumes over the coming year. Read the full article on Seeking AlphaSeeking Alpha • Aug 19
Colgate-Palmolive: Stability Pillar Reached Its Fair Value
Summary Colgate-Palmolive operates globally with a strong presence in over 200 countries, deriving two-thirds of revenue from non-US markets. The Company is a member of the Dividend Kings group, offering reliable dividend income, which grew consecutively for 60 years. Strong organic growth in primary segments (partially offset by FX fluctuations), with profitable operations and solid margins ensuring shareholder rewards. Upon stock price increases during the last couple of quarters, CL's multiple reached its fair level. Therefore, I remain a happy holder, but I've stopped adding. Read the full article on Seeking AlphaPrévisions de croissance des bénéfices et des revenus
| Date | Recettes | Les revenus | Flux de trésorerie disponible | Cash from Op | Moy. Nombre d'analystes |
|---|---|---|---|---|---|
| 12/31/2028 | 22,891 | 3,497 | 3,703 | 4,304 | 11 |
| 12/31/2027 | 22,139 | 3,123 | 3,407 | 3,940 | 17 |
| 12/31/2026 | 21,431 | 3,041 | 2,784 | 3,432 | 17 |
| 3/31/2026 | 20,795 | 2,088 | 3,767 | 4,345 | N/A |
| 12/31/2025 | 20,382 | 2,132 | 3,634 | 4,198 | N/A |
| 9/30/2025 | 20,097 | 2,908 | 3,443 | 4,014 | N/A |
| 6/30/2025 | 19,998 | 2,908 | 3,370 | 3,920 | N/A |
| 3/31/2025 | 19,947 | 2,896 | 3,467 | 4,026 | N/A |
| 12/31/2024 | 20,101 | 2,889 | 3,546 | 4,107 | N/A |
| 9/30/2024 | 20,106 | 2,868 | 3,400 | 3,974 | N/A |
| 6/30/2024 | 19,989 | 2,840 | 3,358 | 3,959 | N/A |
| 3/31/2024 | 19,752 | 2,611 | 3,023 | 3,691 | N/A |
| 12/31/2023 | 19,457 | 2,300 | 3,040 | 3,745 | N/A |
| 9/30/2023 | 19,136 | 1,587 | 2,553 | 3,282 | N/A |
| 6/30/2023 | 18,676 | 1,497 | 2,356 | 3,099 | N/A |
| 3/31/2023 | 18,338 | 1,598 | 2,168 | 2,905 | N/A |
| 12/31/2022 | 17,967 | 1,785 | 1,860 | 2,556 | N/A |
| 9/30/2022 | 17,741 | 1,928 | 2,321 | 2,989 | N/A |
| 6/30/2022 | 17,700 | 1,944 | 2,384 | 3,014 | N/A |
| 3/31/2022 | 17,476 | 2,044 | 2,531 | 3,113 | N/A |
| 12/31/2021 | 17,421 | 2,166 | 2,758 | 3,325 | N/A |
| 9/30/2021 | 17,342 | 2,665 | 2,647 | 3,182 | N/A |
| 6/30/2021 | 17,081 | 2,729 | 2,662 | 3,150 | N/A |
| 3/31/2021 | 16,718 | 2,661 | 3,114 | 3,549 | N/A |
| 12/31/2020 | 16,471 | 2,695 | 3,309 | 3,719 | N/A |
| 9/30/2020 | 16,162 | 2,691 | 3,368 | 3,726 | N/A |
| 6/30/2020 | 15,937 | 2,571 | 3,330 | 3,678 | N/A |
| 3/31/2020 | 15,906 | 2,522 | 2,950 | 3,296 | N/A |
| 12/31/2019 | 15,693 | 2,367 | N/A | 3,133 | N/A |
| 9/30/2019 | 15,489 | 2,330 | N/A | 3,025 | N/A |
| 6/30/2019 | 15,406 | 2,275 | N/A | 3,008 | N/A |
| 3/31/2019 | 15,426 | 2,326 | N/A | 3,045 | N/A |
| 12/31/2018 | 15,544 | 2,400 | N/A | 3,056 | N/A |
| 9/30/2018 | 15,625 | 2,117 | N/A | 2,953 | N/A |
| 6/30/2018 | 15,754 | 2,201 | N/A | 3,046 | N/A |
| 3/31/2018 | 15,694 | 2,088 | N/A | 2,979 | N/A |
| 12/31/2017 | 15,454 | 2,024 | N/A | 3,054 | N/A |
| 9/30/2017 | 15,283 | 2,307 | N/A | 3,119 | N/A |
| 6/30/2017 | 15,176 | 2,402 | N/A | 3,126 | N/A |
| 3/31/2017 | 15,195 | 2,478 | N/A | 3,218 | N/A |
| 12/31/2016 | 15,195 | 2,441 | N/A | 3,141 | N/A |
| 9/30/2016 | 15,373 | 2,461 | N/A | 3,158 | N/A |
| 6/30/2016 | 15,505 | 2,485 | N/A | 3,046 | N/A |
| 3/31/2016 | 15,726 | 2,459 | N/A | 2,836 | N/A |
| 12/31/2015 | 16,034 | 2,468 | N/A | 2,949 | N/A |
| 9/30/2015 | 16,356 | 2,470 | N/A | 3,014 | N/A |
| 6/30/2015 | 16,736 | 2,286 | N/A | 3,132 | N/A |
Prévisions de croissance des analystes
Taux de revenus par rapport au taux d'épargne: La croissance des bénéfices prévue de CL ( 12.1% par an) est supérieure au taux d'épargne ( 3.5% ).
Bénéfices vs marché: Les bénéfices de CL ( 12.1% par an) devraient croître plus lentement que le marché US ( 16.8% par an).
Croissance élevée des bénéfices: Les bénéfices de CL devraient augmenter, mais pas de manière significative.
Chiffre d'affaires vs marché: Le chiffre d'affaires de CL ( 3.2% par an) devrait croître plus lentement que le marché de US ( 11.7% par an).
Croissance élevée des revenus: Le chiffre d'affaires de CL ( 3.2% par an) devrait croître plus lentement que 20% par an.
Prévisions de croissance du bénéfice par action
Rendement futur des capitaux propres
ROE futur: Le retour sur capitaux propres de CL devrait être très élevé dans 3 ans ( 255.3 %).
Découvrir les entreprises en croissance
Analyse de l'entreprise et données financières
| Données | Dernière mise à jour (heure UTC) |
|---|---|
| Analyse de l'entreprise | 2026/05/17 20:30 |
| Cours de l'action en fin de journée | 2026/05/15 00:00 |
| Les revenus | 2026/03/31 |
| Revenus annuels | 2025/12/31 |
Sources de données
Les données utilisées dans notre analyse de l'entreprise proviennent de S&P Global Market Intelligence LLC. Les données suivantes sont utilisées dans notre modèle d'analyse pour générer ce rapport. Les données sont normalisées, ce qui peut entraîner un délai avant que la source ne soit disponible.
| Paquet | Données | Cadre temporel | Exemple de source américaine * |
|---|---|---|---|
| Finances de l'entreprise | 10 ans |
| |
| Estimations consensuelles des analystes | +3 ans |
|
|
| Prix du marché | 30 ans |
| |
| Propriété | 10 ans |
| |
| Gestion | 10 ans |
| |
| Principaux développements | 10 ans |
|
* Exemple pour les titres américains ; pour les titres non américains, des formulaires réglementaires et des sources équivalentes sont utilisés.
Sauf indication contraire, toutes les données financières sont basées sur une période annuelle mais mises à jour trimestriellement. C'est ce qu'on appelle les données des douze derniers mois (TTM) ou des douze derniers mois (LTM). En savoir plus.
Modèle d'analyse et flocon de neige
Les détails du modèle d’analyse utilisé pour générer ce rapport sont disponibles sur notre page Github; nous proposons également des guides expliquant comment utiliser nos rapports et des tutoriels sur Youtube.
Découvrez l'équipe de classe mondiale qui a conçu et construit le modèle d'analyse Simply Wall St.
Indicateurs de l'industrie et du secteur
Nos indicateurs de secteur et de section sont calculés toutes les 6 heures par Simply Wall St. Les détails de notre processus sont disponibles sur Github.
Sources des analystes
Colgate-Palmolive Company est couverte par 43 analystes. 17 de ces analystes ont soumis les estimations de revenus ou de bénéfices utilisées comme données d'entrée dans notre rapport. Les soumissions des analystes sont mises à jour tout au long de la journée.
| Analyste | Institution |
|---|---|
| Christopher Graja | Argus Research Company |
| Lauren Lieberman | Barclays |
| Lauren Lieberman | Barclays |